newsfilter
← Latest News
Earnings Call Transcripts·

Topline Results from the Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia - MAPLIGHT THERAPEUTICS INC

Good day, and welcome to the top-line results from the Phase 2 Zephyr Study of ML007C, MA and Schizophrenia. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a quest

Company
MAPLIGHT THERAPEUTICS INC
Keywords
MAPLIGHT THERAPEUTICS INC